These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35746482)

  • 1. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
    Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.
    Reinholm A; Maljanen S; Jalkanen P; Altan E; Tauriainen S; Belik M; Skön M; Haveri A; Österlund P; Iakubovskaia A; Pasternack A; Naves RA; Ritvos O; Miettinen S; K Häkkinen H; Ivaska L; Tähtinen PA; Lempainen J; Kantele A; Kakkola L; Julkunen I; Kolehmainen P
    Commun Med (Lond); 2024 Feb; 4(1):28. PubMed ID: 38396065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
    Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
    Lapa D; Grousova DM; Matusali G; Meschi S; Colavita F; Bettini A; Gramigna G; Francalancia M; Garbuglia AR; Girardi E; Puro V; Antinori A; Kovyrshina AV; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Gushchin VA; Logunov DY; Naroditsky BS; Vaia F; Gintsburg AL
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada.
    Rabezanahary H; Gilbert C; Santerre K; Scarrone M; Gilbert M; Thériault M; Brousseau N; Masson JF; Pelletier JN; Boudreau D; Trottier S; Baz M
    Heliyon; 2024 May; 10(10):e31026. PubMed ID: 38826717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection.
    Vicenti I; Basso M; Dragoni F; Gatti F; Scaggiante R; Fiaschi L; Parisi SG; Zazzi M
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
    Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
    medRxiv; 2022 Jan; ():. PubMed ID: 35018383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
    Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.
    Lopera TJ; Chvatal-Medina M; Flórez-Álvarez L; Zapata-Cardona MI; Taborda NA; Rugeles MT; Hernandez JC
    Front Immunol; 2022; 13():879036. PubMed ID: 35585980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
    Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
    BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
    Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
    medRxiv; 2021 Jul; ():. PubMed ID: 34373860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents.
    Sánchez-Sendra B; Albert E; Zulaica J; Torres I; Giménez E; Botija P; Beltrán MJ; Rodado C; Geller R; Navarro D
    Sci Rep; 2022 Mar; 12(1):3788. PubMed ID: 35260713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
    Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Franchi F; Cusi MG
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.